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The human bcl-2 (B-cell lymphoma/leukaemia-2) 
gene was identified at the breakpoint site of the 
t(14;18) chromosomal translocation that is associ- 
ated with follicular lymphoma. In this translocation, 
bcl-2 moves from its normal location at 18q21 into 
juxtaposition with the lmmunogiobulin heavy-chain 
locus at 14(;132 (Ref. 1), which results in its transcrip- 
tional activation and the overproduction of the 26 
kDa Bcl-2 protein in iymphoma cells z,-~. 
Bcl-2 is thought to contribute to oncogenesis by 
suppressing signals that induce apoptotic cell death. 
(For an introduction to apoptosis, see the box in the 
first article of this series In TCB, by McConkey and 
OrRnius.) For example, overexpresslon of bcl.2 can 
prevent haematopoletlc and neural cell apoptosis 
Induced by growth factor withdrawal *~, and bci.2 
also prevents or delays apoptosls induced by ,/-Ir- 
radiation, glucocorticolds, heat shock and mult iple 
chemotherapeutic drugs 74°. 
The regulation of cell death by Bcl-2 has been con- 
served among divergent phyla. As discussed In the 
previous article on apoptosls by Osborne and 
Schwartz, the genes ced.3 and ced.4 are required 
for developmental cell death In the nematode 
Caenorhabditis elegans, whereas the ced.9 gene Is a 
negative regulator of such deaths. It is now known 
that ced.3 is homologous to the gene encoding 
the mammalian Interleukin-ll3-converting enzyme 
(ICE), while ced-9 Is homologous to bcl-2. Indeed, 
overexpression of bcl.2 in the worm prevents ced-3- 
an.:! ced.4.dependent cell death; and overexpression 
of bcl-2 In vertebrate cells prevents apoptosis induced 
by ICE overexpression. 
This article summarizes recent progress in charac- 
terizing gene products related to Bcl-2, examines the 
role of Bcl-2 in normal development and In onco- 
genesis, and then discusses the possible mechanisms 
of action of Bcl-2 in regulating apoptosis. 
The growing fami ly  of /~r / .2 . re la ted  genes 
bci-2 was the founding member of an expanding 
fami ly of genes, which now includes bcl.x, bax, 
incl.1 and A1, that regulate apoptosis. The homology 
among the Bcl-2-related proteins is concentrated 
in two regions, termed BH1 and BH2 (Fig. 1). In 
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The Bcl-2 protein inhibits apoptosis induced by a variety of 
signals, in a range of cell types and in diverse organisms, and it is 
implicated in both normal development and oncogenesis. Despite 
this central role, the mechanism of action of Bcl-2 is not yet clear. 
Recent studies have uncovered a number of Bci.2.related gene 
products that regulate apoptosis either negatively or positively, and 
Bcl.2 forms heterodimers with at least one of these proteins, Bax. 
This article discusses the role of the Bcl.2 family of proteins in the 
light of these findings. 
addition, proteins of the Bcl-2 family contain a stretch 
of hydrophobic amino acids at their C-termini, 
which appear important for attachment to Intra- 
cellular membranes !1,1z. 
bci.x was recently isolated by hybridization to a 
bci-2 probe ~3 and by functional expression cloning 
(M. Gonz~lez-Garcia and G. Nuflez, unpublished). It 
gives rise to three transcripts by alternative splicing. 
The predicted Bcl-x L protein displays high-level 
homology to Bcl-2. As with bcl.2, transfection of bci- 
x L into IL.3.dependent cells prevented their apop- 
totic cell death following growth factor depri- 
vation ~3,~4. The predicted Bcl-x s protein lacks the 
internal re'glon'o~f 63 amino acids in BCI-x L that has 
greatest homology to Bcl-2. Surprisingly, transfec- 
tion of bcl-x s failed to inhibit cell death; rather, it 
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Regions of homology between Bcl-2 and related proteins. The amino acid 
sequences for human Baxo, Bcl.xLand Mcl-1 and murine A1 are aligned with 
human Bcl-2.. Identical amino acids shared by three or more sequences are 
shown in bold, and stippled. The regions of greatest homology among Bcl.2. 
related proteins, BH1 and BH2, a,e boxed. The arrows indicate a region of 63 
amino acids of Bcl-x L that is not present in Bcl.x s (Ref. 13). 
facilitated apoptosls by Inhibiting the death suppres. 
sor activity of Bcl-2 (Ref. 13), perhaps by competing 
for Its targets or positive regulators. The predicted Bcl% 
protein lacks the hydrophoblc C-terminal domain 
present in Bcl.x L and Bcl-x s (Ref. 14). bcl.x a also 
inhibits apoptosts induced by growth factor depri. 
ration (M. Gonzltlez.Garcia et al., unpublished). 
The Bax protein was identified by lmmunopreclpl. 
ration of Bcl-2 (Ref. 15). Bax is a 21 kDa protein with 
21% homology to Bcl-2 and forms heterodimers with 
Bcl-2 (Ref. 15). Importantly, expression of bax does 
not block apoptosls; instead it appears to inhibit the 
function of Bcl-2, perhaps by forming Bcl-2-Bax com- 
plexes or by competing with other Bcl-2 targets (see 
below). 
The incl.1 and A! genes were isolated by differen, 
tlal hybridization, incl.1 encodes a 37 kDa protein 16 
and A1 encodes a 20 kDa protein 17, both of which 
display significant homology to Bcl-2 and Bci.x u par. 
tlcularly in the BH1 and BH2 domains (Pig. 1). rod.1 
and A I are early-response genes that are induced 
transiently by differentiation signals or growth fac- 
torsX6.*L mcl-1 appears to inhibit apoptosls (R, Craig 
and A. Eastman, pets. commun.), Overexpression of 
AI in IL-3-dependent cell lines delays their apoptotlc 
death induced by growth factor withdrawal (M, 
Benedict and G. Nufiez, unpublished). 
Thus, the regulation of apoptosls in vertebrates by 
bcl.2 and related genes is complex and involves posi- 
tive and negative functions. It is possible that further 
lx'l.2-related genes will be identified in the near future. 
Bcl-2 function in v/vo 
The expression of the bcl-2 gene is widespread in 
many fetal tissues 18, but in adult tissues bcl-2 appears 
to be expressed in cells that are rapidly dividing and 
differentiating into mature components (Table 1). 
Such cells include stem ceils of the crypts of the gut 
epithelia or the skin, and early haematopoietic pro- 
genitors 19. bd-2 expression declines in cells as they 
mature, or at stages when cells may be eliminated. 
For example, bcl-2 is downregulated during kera- 
tinocyte or myeloid differentiation19; and transiently 
during B and T cell differentiation, at a stage when 
such cells are prone to undergo clonal elimination by 
apoptosis z°-2z. Taken together, these observations 
have led to the hypothesis that Bcl-2 is a survival 
favor for early progenitor cells and for fully differ- 
entiated cells that are long-lived. Conversely, down- 
regulation of Bcl-2 during tissue differentiation 
appears to facilitate cell death that occurs during 
clonal selection or that is coupled to terminal differ- 
entiation of epithelial or haematopoietic tissues. 
bcl-x mRNA is produced in a variety of tissues in 
the chicken, human and mouse 130~4. In the mouse, 
bcl-x L is the major bcl-x mRNA form expressed during 
embryonic and postnatal development, and in the 
adult it is highly expressed in the brain, kidney, bone 
marrow and thymus ~4. The expression of bcl-x L in the 
adult central nervous system (CNS) ~4 contrasts with 
the low ok undetectable expression of bcl.2 in most 
neurons of the CNS. Both murlne bcl.x L and bci.x a are 
highly expressed in bone marrow and thymus but 
downregulated in spleen and lymph nodes 14. 
Mice lacking functional Bcl-2 (bcl.2 'knockouts') 
have given further Insight Into the biological funo 
tlons of bcl.2. Surprisingly, such mice developed nor. 
really to birth, but died at two to ten weeks of age 
due to fulminate apoptosis of lymphoid tissues and 
polycystlc kidney disease 24,2s, Why other tissues that 
normally express large amounts of Ix'l.2, such as the 
nervous system or the bone marrow, are unaffected 
in such mice is not known, One plausible expla. 
nation is that there is a redundancy built into the 
bcl.2 pathway, an idea supported by the overlapping 
expression of bcl-x and bcl.2 in many tissues. It is 
possible that IM.x, or other bcl.2 family members, are 
involved in the normal homeostasis of tissues that 
are not affected in the bcl.2 knockouts. Ongoing 
experiments with mli:e containing disrupted mu. 
tatlons of the various bcl.2 family members should 
clarify this issue, 
be/.2 and oncogenesis 
Malignant transformation can be thought of as 
arising from activation of the cell's mitogenic 
machinery and inactivation of the ~owth-inhibito W 
and apoptosis machinew, through multiple mu- 
tations, For example, in breast cancer, two of the 
most common abnormalities are deregulated ex- 
pression of omyc and inactivation or mutation of the 
pS3 turnout suppressor gene a6. Expression of the gene 
encoding pS3 or certain oncogenes such as c-myc car 
induce s~me cancer cells to undergo apoptosisZT-~o 
which suggests that the cell death programme 
is a critical defence mechanism against malignant 
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TABLE 1 - CHARACTERISTICS OF THE k l - 2  AND RELATED GENE PRODUCTS 
Gene Gene product Function Expression d Subcellular location Refs 
bcl-2 Bcl-2 Blocks apoptosis Widespread in embryonic tissues Outer mitochondria, 18 





Bcl-x L Blocks apoptosis 
Bcl-x s Promotes apoptosis 
Bcl-xl~ Blocks apoptosis a 
Box Promotes apoptosis 
A1 Blocks apoptosis b 
Mcl-1 Blocks apoptosis c 
Widespread in embryonic tissues 
Highly restricted in postnatal tissues 
Human thymus 
Same as Bcl-x L 
Widespread 
Hematopoietic tissues 















aGonz~lez-Garc/a, M. et oL, unpublished. 
bM. Benedict and G. Nufiez, unpublished. 
CR. Craig and A. Eastman, pers. commun. 
dExpression of box, bcl-x, A1 and md.l at the RNA level. 
eDetailed anaiysis in tissues not yet carried out. 
transformation. Many types of turnouts, including 
most breast carcinomas, produce Bcl-2 (Ref. 31). 
Although bcl-2 alone does not stimulate cell pro- 
liferation or cause transformation, it cooperates 
with c-myc 4,32,33 and members of the ras family 34 to 
transform cells. Recently it has been shown that 
bci-2 protects cells from c-myc- and pS3-induced 
apoptosis 33.3s'ag, which suggests that Bcl-2 suppresses 
apoptosls signals that occur wi th transformation. 
In addition to a role in the genesis of cancers, the 
modulat ion of apoptosis may also influence the out- 
come of cancer treatment. Elegant studi,~s with p53 
"knockout' mlc~ showed that X.lrradlatlon and certain 
chemotherapeutic agents kill cells through the pS3- 
dependent apoptosls pathway :~9,~°. In contrast, the ex- 
pression of bcl.2 has been shown to protect cells from 
both chemotherapy and radiation-induced apop- 
tosis 7,9,~o,13. Because Bd.2 production Is a common 
feature of many carcinomas, lymphomas 
and leukaemlas, it is thought that Bd-2 
might play a role in the resistance to 
I therapy. Indeed, expression of bcl.2 in leukaemia, carcinoma of the prostate andneuroblastoma has been shown to be a marker for poor prognosis 41-44. 
Cellular distribution of the Bcl.2 protein 
Bcl-2 is a stable protein zl associated with 
organdies, especially mitochondrial  
FIGURE 2 
membranes. It is now known to reside primarily in 
the outer mitochondrial membrane, nuclear envelope 
and endoplasmic reticulum (ER) ~s,46. Recent electron 
microscopy studies indicate that Bcl-x L has a sub- 
cellular distribution similar to that of Bcl-2 (Ref. 14), 
which suggests that both proteins function in a sirni- 
lar manner to prevent cell death (Fig. 2). In vitro and 
in vivo studies showed that amino acids 187 to 216 
of Bcl-2 are crucial for correct integration of its 
hydrophobic C-terminus into the membrane 11,]2. 
The N.terminus of the integrated protein is exposed 
to the cytosoPL Interestingly, during mitosis Bcl-2 
may contact chromosomes 48, although the import- 
ance of this finding remains unknown. 
The functional significance of Bcl-2 targeting to the 
outer membrane of cell organeiles is also unclear. 
Deletion of the hydrophobic C.termlnus of 
Bcl-2 abrogates much, but probably not all, of the 
How does k l - 2  prevent apoptosls? 
The global changes in many cellular 
processes that occur during apoptosis 
make it difficult to distinguish cause 
from effect. Nevertheless, several rood- 
els have been proposed to explain the 
inhibition of apoptosis by Bcl-2. Here 
we discuss clues to the function of Bcl- 
2 from knowledge of its cellular distri- 
bution, and then turn to possible mech. 
anisms of Bcl-2 action. 
,~!!i!!!i!ii!iiii!iiill ¸!i !i!i!iiil ¸l  
Localization of Bcl-2 and Bcl-x L to intracellular membranes. Confocal images of F1.5.12 cells 
transfected with human bcl.2 or FLAG-tag-bd-x c are shown. Cells were permeabilized, and stained 
with (A) 6C8 (anti-Bcl-2) or (B) M2 (anti.FLAG) antibodies. The staining pattern of Bcl-2 and 
Bcl.x L is granular and extranuclear, consistent with localization of Bcl-2 and Bcl-x L to cytoplasmic 
organelles. Dual labelling experiments and electron microscopy have shown that Bcl-2 and Bcl-x L 
localize primarily to the outer membrane of mitochondria, the ER and the nuclear envelope (see 
Table 1 for details and references). 
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FIGURE 3 
Model of apoptosis based on the interaction of Bcl-2 and Myc with pS3. In 
mouse erythroleukaemia cells, pS3 arrests cells in the G1 phase of the cell cycle, 
and induces apoptosis. [Arrest results from downregulation of c-my¢ expression, 
which Is obligate for cell cycle progression, and upregulation of Clpl expression 
(Clpl binds to cyclins and inhibits cell cycle progression).] The ability of pS3 to 
induce apoptods Is independent of Its cell cycle arrest function. Cells that 
coexpress pS3 and bd.2 are growth arrested, but apoptosis is delayed 3s. 
p$3 Is nuclear In these cells. We suggest that p53 activates an effector of 
apoptosls that Is Inhibited by Bcl-2. By contrast, cells that coexpress genes 
encoding p53, Bcl.2 and Myc continue to proliferate and do not undergo 
apoptosls 38. In such cells, p53 Is cytoplasmic during G1 when cells are 
susceptible to p$3-1nduced apoptosls and growth arrest 38. We postulate that 
Myc induces or activates a factor that cooperates with Bcl.2 to block p53 
transport across the nuclear membrane, 
protective effects of the Bcl-2 protein u,~2, It is not 
clear whether the residual function of the mutant 
proteins results from interaction with cytoplasmic 
targets or integration of a small amount of the 
mutant protein into organelle membranes. 
Interestingly, Bcl-2 prevents the appearance of mor- 
phological changes characteristic of apoptosis in cells 
that do not contain mitochondrial DNA 49 or nuclei s0, 
Bcl.2.interacting proteins 
Recently, Bcl-2 has been shown to bind to two pro- 
teins: Bax and R-Ras. These observations have given 
insight into how Bcl.2 functions. As discussed above, 
increased levels of bax expression appear to counter- 
act the effects of Bcl-2 and to promote, rather than 
inhibit, apoptosis ~s, Substitution of Gly145 of the 
BHI domain or Trp188 of the BH2 domain of Bcl-2 
functionally inactivates the protein s~, and these 
mutants cannot bind Bax but can still form Bcl.2 
homodimers s2. These results can be interpreted in 
three ways. First, it is possible that the Bcl-2 homo- 
dimer is normally the functional complex, but 
that the mutated homodimers are not fully active. 
Second, the Bcl-2-Bax heterodimer may be the func- 
tional complex and the Bax-Bax homodimer may be 
a negative regulatorSL Third, the domains of Bcl-2 
that interact with Bax might allow Bcl-2 to dimerize 
with another factor to form an active complex. In 
this latter case, neutralization of Bcl-2 by box over- 
expression may be explained by competition be- 
t w i n  Bax and the other Bcl-2 partner for B(~-2. The 
modulation of Bcl-2 activity by its partners may 
explain why Bcl-2 fails or is very poor in inhibiting 
some forms of apoptosis s.8. 
The Bcl-2 protein also associates with the C-ter- 
minal 60 amino acids of the R-Ras protein, a 23 kDa 
membrane protein that is SS% homologous to Ha- 
Ras sz. The Ras protein family consists of more than 
S0 proteins that regulate many diverse processes, 
such as cellular proliferation and differentiation, 
cytoskeletal control, and intracellular vesicular traf- 
ticking. Understanding of the consequences of the 
Bcl-2-R-Ras interaction awaits discovery of the func- 
tion of the R-Ras protein. 
Bcl-2 and oxygen free radical metabolism 
As discussed in the article by McConkey and 
Orrenius, reactive oxygen species are thought to be 
involved in apoptosis. Recently, it has ~been postu- 
lated that Bcl-2 inhibits cell death by act-]t~g as an 
antioxidant s3 or inhibit ing the generation of oxygen 
free radicals s4. In haematopoietic cells under- 
going apoptosis after exposure to various apoptotic 
signals, overexpression of bd.2 was assoctatecl with 
decreased oxidative damage to cellular constituents, 
but was not associated with decreased formation 
of reactive oxygen Intermediates s3. However, in 
neuronal cells undergoing necrosis as a result of 
glutathlone depletion, expression of bcl.2 was as- 
sociated with both decreased generation of oxygen 
free radicals and decreased oxidative damage to 
cellular constltuents s4. Thus, Bcl-2 appears to 
function as an antloxidant, However, it is unclear 
whether Bcl-2 protects against death specifically 
Induced by reactive oxygen species and, indeed, 
whether reactive oxygen intermediates are required 
for apoptosis. 
Bcl.2 and intmceUular C~+ 
Bcl.2 may inhibit apoptosh by aitedng Ca z÷ fluxes 
through lntracellular organeJ]es. In some exper- 
imental systems, the release of Ca z~ tram a mobiliz- 
able pool located in the ER has been associated with 
apoptosis (see Orrenius and McConkey's article). 
Bcl-2 is located in ER membranes and its overpro. 
ductlon interfeRs with the efflux of Ca 2÷ across ER 
membranes in cells undergoing apoptosis ss,s6. 
8cl-2 and modulation of subcellular tlafficking 
The idea that Bcl-2 may play a role in nuclear 
~lansport came from lmmunohistochemistry studies 
su88estln 8 that Bclo2 might be localized to nuclear 
pores 4s. Bcl-2 has recently been shown to alter the 
nucleocytoplasmic trafficking of p53 (Ref. 38) and 
the cdc2 and CD[C?. cell cycle regulatory proteins s7. 
Coexpression of bcl-2 with the gene encoding pS3 
delayed pS3-induced apoptosis, but did not affect 
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p53 trafficking to the nucleus nor pS3-induced 
growth arrest; however, Bcl-2 and Myc cooperated to 
block p53 entry into the nucleus and thus prevented 
p53-induced apoptosis and growth arrest 3s. We specu- 
late that Bcl-2 inhibits an effector of apoptosis that 
is activated by p53, and that Myc induces or activates 
afactor that cooperates with the membrane protein 
Bcl-2 to modulate the transport pathway responsible 
for the entry of p53 into the nucleus (see Fig. 3). 
Future d l r e d i o n s  
Remarkable progress has been made in under° 
standing the role that Bclo2 and its family members 
play in regulating apoptosis and how this contributes 
to embryonic development, adult tissue homeostasis, 
and carcinogenesis. Apoptosis is characterized by 
changes in multiple cellular processes. It follows that 
Bcl-2 must block a single critical step that initiates 
these many events, or that it blocks all of the mul- 
tiple events that together trigger apoptosis. A com- 
plete understanding of the factors with which Bcl-2 
family members interact, and how these interactions 
regulate the mediators of apoptosis, will distinguish 
between these possibilities and lead to new insight 
into this unique cell viability regulatory system. 
References 
1 TSUJlMOTO, Y., COSSMAN, E., IAFFE, E. and CROCE, C. M. 
(1985) Science 228, 1440-1443 
2 SETO, M. et ol. (1988) EMBOI. 7, 123-131 
3 CHEN-LEW, Z., NOURSE, I. and CLEARY, M. L. (1989) Mol. Cell. 
Biol. 9, 701-710 
4 VAUX, D. L., CORY, S. and ADAMS, J. (1988) Nature 325, 440-442 
$ NUI~IEZ, G., LONDON, L., HOCKENBERY, D., ALEXANDER, M., 
MCKEARN, J. P. and KORSMEYER, S. J. (199~)J. Immunol. 144, 
3602-3610 
6 GARC[A0 I., MARTINOU, I., TSUJlMOTO, Y. and MARTINOU, J. C. 
(1992) Science 258, 302-304 
7 SENTMAN, C. L., SHUTrEI~ J. R.0 HOCKENBERY, D., 
KANAGAWA, O. and KORSMEYER, S. J. (1994) Cell 67, 879-888 
g CUENDE, E., ALES.MARTINEZ, J. E., DING, L., 
GONZALEZ.GARCIA, M., MARTINEZ.A, C. and NUI~EZ, G. 
(1993) EMBO I. 12, 1555-1560 
9 MIYASHITA, T. and REED, J. C. (1992) Catlcer ~es. 52, 5407-5411 
10 DOLE, M. G. etal. (1994) CancerRes. 54, 3253-3259 
11 NGUYEN, M., MILLAR, D. G., YONG, V. W., KORSMEYER, S. J. 
and SHORE, G. C. (1993)I. Biol. Chem. 268, 25265-25268 
12 TANAKA, S., SAITO K. and REED, J. C. (1993)/. Biol. Chem. 268, 
10920-10926 
13 BOISE, L. H. et al. (1993) Cell 74, 597-608 
14 GONZALEZ-GARCIA, M. etal. (1994) Development 20, 3033--3042 
15 OL'IVAI, Z. N., MILUMAN, C. L. and KORSMEYER, S. J. (1993) 
Cell 74, 609-619 
16 KOZOPAS, K. M., YANG, T., BUCHAN, H. L. ZHOU, P. and 
CRAIG, R. W. (1993) Proc. NotlAcod. Sci. USA 90, 3516-3520 
17 UN, E. Y., ORLOFSKI, A., BERGAR, M. and PRYSTOWSKY, M. B. 
(1993) I. ImmunoL 151, 1979-1088 
18 LEBRUN, D. P., WARNKE, R. A. and CLEARY, M. L. (1993) Am. J. 
Pathol. 142, 743--753 
19 HOCKENBERY, D., ZUTTER, M., HICKEY, W., NAHAM, M. and 
KORSMEYER, S. J. (1991) Proc. NatlAcad. Sd. USA 88, 6961-6965 
20 GRATIOT.DEANS, J., DING, L., TURKA, L. A. and NUI~EZ, G. 
(1993) I. Immunol. 151, 83-91 
21 MERINO, R., DING, L., VEIS, D. l., KORSMEYER, S. J. and 
TRENDS IN CELL BIOLOGY VOI.. 4 NOVEMBER 1994 
NUI~IF.Z, G. (1994) EMBOI. 13, 683-691 
22 NUNEZ, G., MERINO, R., GRILLOT, D. and 
GONZALEZ-GARCIA, M. Immunol. Today (in press) 
23 MERRY, D. E., VEIS, D. J., HICKEY, F. and KORSMEYER, S. J. 
(1994) Develc, pment 120, 301-311 
24 VEIS, D. J., SORENSON, C. M., SHUTTER, J. R. and KORSMEYER, 
S. J. (1993) Cell 75, 229-240 
25 NAKAYAMA, K. etal. (1994) Proc. Natl Acad. Sd. USA 
91, 3700-3704 
26 MAZARS, R., SPINARDI, L, BENCHEIKH, M., 
SIMOY-LAFONTAINE, J., JEANTUR, P. and THILLET, C. (1992) 
Cancer lies. 52, 3918-3923 
27 YONISH-ROUACH, E. et al. (1991) Nature 352, 345-347 
28 RYAN, J. J., DANISH, R., GO'I'I'UEB, C. A. and CLARKE, M. F. 
(1993) Mol. Cell. Biol. 13, 711-719 
29 EVAN, G. I. et al. (1992) Cell 69, 119-128 
30 TANAKA, N. et al. (1994) Cell 77, 829-849 
31 SIVESTRINI, R. etal. (1994)1. NaL Cancerlnst. 86, 499-504 
32 NUNEZ, G. et al. (1989) Ptoc. Natl Acad. Sci. USA 86, 4589-4593 
33 FANIDI, A., HARRINGTON, E. A. and EVAN, G. I. (1992) Nature 
359, 554-556 
34 REED, J. C., HALDAR, S., CROCE, C. M. and CUDDY, M. P. 
(1990). Mol. Cell. BioL 10, 4370-4374 
35 BISSONNETTE, R. P., ECHEVERRI F., MAHBOUBI, A. and 
GREEN, D. R. (1992) Nature 359, 552-554 
36 WANG, Y., SZEKELY, L., OKAN, I., KLEIN, G. and WlMAN, K. G. 
(1993) Oncogene 8, 3427-3431 
37 CHIOU, S.K., RAO, L. and WHITE, E. (1994) Mol. Cell. Biol. 14, 
2556-2563 
38 RYAN, J. J. etal. (1994) Proc. NatlAcad. Sci. USA 91, 5878-5882 
39 LOWE, S. W., SCHMI'n', E. M., SMITH, S. W., OSBORNE, B. A. 
and lACKS, T. (1993) Nature 362, 847-849 
40 CLARKE, A. R. et aL;(1993) Nature 362, 849-852 
41 CAMPOS, L. oral. (1993) Blood81, 3091-3096 
42 MCDONNELL, T. etal. (1992) Cancer Res. 52, 6940-6944 
43 COLOMBEL, M. et al. (1993) Am. I. Pathol. 143, 390-396 
44 CASTLE, V., HEIDELBERGER, K. P., BROMBERG, J., DOLE, M. 
and NUI~EZ G. (1993) Am. I. Pathol. 143, 1543-1SS0 
45 KRAJEWSKI, S., TANAKA, S., SCHIBLER, M. J., FENTON, W. and 
hEED, I. C. (1993) Cancer Res. 53, 4701-4714 
46 MONAGHAN, P., AMOS, T. A., DYER, M. I., MASON, D. Y. and 
GREAVES, M. F. (1992)I. Histochem. Cytochem. 40, 1819-1825 
47 CHEN.LEW, Z. and CLEARY, M. L. (1990)1. Biol. Chem. 265, 
4929-4933 
48 WlLLINGHAM, M. C. and BHALLA, K. (1994)/. Histochem. 
Cytochem. 42, 441-450 
49 JACOBSON, M. D., BURNE, J. F., KING, M. P., MIYASHITA, T., 
REED, J. C. and RAFF, M. C. (1993) Nature 361,365-369 
50 JACOBSON, M. D., BURNE, J. F. and RAFF, M. C. (1994) EMBO 
J. 13, 1899-1910 
Sl YIN, X. M., OLTVAI, Z, N. and KORSMEYER, S. J. (1994) Nature 
369, 321-323 
52 FERNANDEZ-SARABIA, M. J. and BISCHOFF, J. R. (1993) Nature 
366, 274-275 
$3 HOCKENBERY, D. M., OL'WAI, Z. N., YIN, X. M., 
MILLIMAN, C. L. and KORSMEYER, S. J. (1993) Cell 75, 241-251 
54 KANE, D. J. et ol. (1993) Science 262, 1274-1277 
55. BAFFY, G., MIYASHITA, T., WILUAMSON, J. R. and REED, J. C. 
(1993) I. Biol. Chem. 268, 6511-6519 
56 LAM, L., DUBYAK, G., CHEN, L., NUNEZ, G., MIESFELD, R. L 
and DISTELHORST, C. W. (1994) Proc. Nail Acod. Sci. USA 91, 
6569-6573 
57 MEIKRANTZ, W., GISSELBRECHT, S., TAM, S. and SCHLEGEL R. 
(1994) Proc. Natl Acad. Sci. USA 91, 3754-3758 
Acknowledgements 








and other members 




authors are funded 






The Council for 
Tobaccn Pes,:arch 
USA. Gabriel Nuflez 
is suppolted in part 
by a Research 
Career 
Development 
Award from the 
NIH. 
403 
